Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Flex Pharma Inc    FLKS

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/10/2017 10/11/2017 10/12/2017 10/13/2017 10/16/2017 Date
3.38(c) 3.47(c) 3.36(c) 3.44(c) 3.36(c) Last
16 097 22 726 24 002 17 391 30 043 Volume
+0.30% +2.66% -3.17% +2.38% -2.33% Change
More quotes
Financials ($)
Sales 2017 1,73 M
EBIT 2017 -40,6 M
Net income 2017 -37,7 M
Debt 2017 -
Yield 2017 -
Sales 2018 5,23 M
EBIT 2018 -50,6 M
Net income 2018 -49,9 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 34,8x
Capi. / Sales2018 11,6x
Capitalization 60,4 M
More Financials
Company
Flex Pharma, Inc. operates as a biotechnology company.It engages in developing treatments for exercise-associated muscle cramps, nocturnal leg cramps and spasms associated with severe neuromuscular conditions.The company operates through two segments: Consumer Operations and Drug Development.The... 
More about the company
Surperformance© ratings of Flex Pharma Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on FLEX PHARMA INC
10/16 FLEX PHARMA : Initiates CMT Phase 2 Trial with FLX-787 in US
09/25 FLEX PHARMA,INC. (NASDAQ : FLKS) Files An 8-K Regulation FD Disclosure
09/25 FLEX PHARMA, INC. : Regulation FD Disclosure, Financial Statements and Exhibits ..
09/11 FLEX PHARMA : Presenting at Upcoming Investor Conferences in September 2017
09/06 FLEX PHARMA : Presenting at Upcoming Investor Conferences in September 2017
08/28 FLEX PHARMA,INC. (NASDAQ : FLKS) Files An 8-K Departure of Directors or Certain ..
08/28 FLEX PHARMA, INC. : Change in Directors or Principal Officers (form 8-K)
08/03 FLEX PHARMA : to Report Second Quarter 2017 Results on August 2, 2017
08/03 FLEX PHARMA : Initiates ALS Phase 2 Trial with FLX 787 in US
08/03 FLEX PHARMA : Names William McVicar President and Chief Executive Officer
More news
Sector news : Bio Therapeutic Drugs
10/05DJAppeals Court Rules Against Amgen in Patent Case -- Update
10/05DJAppeals Court Rules Against Amgen in Patent Case
09/29 Merck to stop development of hepatitis C treatments
09/20DJSANOFI : Alnylam Report Positive Patisiran Phase III Trial, First-Ever for RNAi ..
09/15 Drug industry on tenterhooks as Maryland price-gouging law nears
More sector news : Bio Therapeutic Drugs
Latest Tweets
10/16Flex Pharma Initiates CMT Phase 2 Trial with FLX-787 in US  
10/16BRIEF-Flex Pharma initiates CMT phase 2 trial with FLX-787 in US  
10/16Flex Pharma Initiates CMT Phase 2 Trial with FLX-787 in US: BOSTON--(BUSINESS.. 
10/16Flex Pharma Initiates CMT Phase 2 Trial with FLX-787 in US  
10/14Analysts Set Flex Pharma, Inc. $FLKS Target Price at $16.80  
More tweets
Qtime:72
News from SeekingAlpha
09/12 Flex Pharma (FLKS) Presents At Rodman & Renshaw 19th Annual Global Investment..
09/06 Midday Gainers / Losers
08/05 Flex Pharma 2017 Q2 - Results - Earnings Call Slides
08/05 Flex Pharma's (FLKS) CEO Bill McVicar on Q2 2017 Results - Earnings Call Tran..
08/02 Flex Pharma beats by $0.07, misses on revenue
Chart FLEX PHARMA INC
Duration : Period :
Flex Pharma Inc Technical Analysis Chart | FLKS | US33938A1051 | 4-Traders
Technical analysis trends FLEX PHARMA INC
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 19,6 $
Spread / Average Target 483%
EPS Revisions
Managers
NameTitle
William K. McVicar President, Chief Executive Officer & Director
Christoph H. Westphal Chairman
John McCabe Chief Financial Officer & Treasurer
Thomas C. Wessel Chief Medical Officer
Peter Barton Hutt Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
FLEX PHARMA INC-34.85%60
GILEAD SCIENCES13.35%106 002
REGENERON PHARMACEUTICALS20.67%47 464
VERTEX PHARMACEUTICALS107.56%38 551
ACTELION23.24%29 919
GENMAB22.08%13 910